Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CStone Pharmaceuticals ( (HK:2616) ) has provided an announcement.
CStone Pharmaceuticals announced the development of two bispecific antibodies, CS2013 and CS2015, targeting autoimmune and inflammatory diseases. These candidates, which have advanced to the preclinical candidate nomination stage, represent a strategic expansion into non-oncology therapeutic areas. CS2013 targets B-cell-mediated autoimmune diseases, while CS2015 addresses Th2-mediated inflammatory diseases. Both antibodies show potential for best-in-class or first-in-class status, with promising preclinical data indicating extended half-life and subcutaneous delivery potential. This development aligns with CStone’s vision to enhance global patient health through innovation.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in 2015 and listed on HKEX, is an innovation-driven biopharmaceutical company focused on anti-cancer therapies. The company has launched four innovative drugs and secured approvals for 16 new drug applications across nine indications. CStone’s pipeline includes potentially first-in-class or best-in-class antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines. The company is committed to addressing unmet medical needs in China and globally, supported by a management team with comprehensive drug development expertise.
Average Trading Volume: 12,225,589
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.73B
For an in-depth examination of 2616 stock, go to TipRanks’ Overview page.